Cutaneous T cell lymphoma staging
Jump to navigation
Jump to search
|
Cutaneous T cell lymphoma Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
The staging of cutaneous T cell lymphoma is based on skin and lymph node involvement.[1]
Staging
The staging of cutaneous T cell lymphoma is based on skin and lymph node involvement.[1] Staging for cutaneous T cell lymphoma is provided in the following table:[2][3][4]
| Staging for mycosis fungoides and Sezary syndrome | ||
|---|---|---|
| Skin (T) | ||
| T1 | Limited patches, papules, and/or plaques covering <10% of the skin surface. May further stratify into T1a (patch only) versus T1b (plaque patch) | |
| T2 | Patches, papules, or plaques covering 10% of the skin surface. May further stratify into T2a (patch only) versus T2b (plaque patch). | |
| T3 | One or more tumours (1-cm diameter) | |
| T4 | Confluence of erythema covering 80% body surface area | |
| Node (N) | ||
| N0 | No clinically abnormal peripheral lymph nodes; biopsy not required | |
| N1 | Clinically abnormal lymph nodes; histopathology Dutch grade 1 or NCI LN0-2 | |
| N1a | Clone negative | |
| N1b | Clone posetive | |
| N2 | Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3 | |
| N2a | Clone negatove | |
| N2b | Clone posetive | |
| N3 | Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3e4 or NCI LN4; clone positive or negative | |
| NX | Clinically abnormal peripheral lymph nodes; no histologic confirmation | |
| Visceral (M) | ||
| M0 | No visceral organ involvement | |
| M1 | Visceral involvement (must have pathology confirmation and organ involved should be specified) | |
| Blood (B) | ||
| B0 | 0 Absence of significant blood involvement: 5% of peripheral blood lymphocytes are atypical (Sezary) cells B0a Clone negative B0b Clone positive | |
| B1 | Low blood tumour burden: >5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2 B1a Clone negative B1b Clone positive | |
| B2 | High blood tumour burden: 1000/mL Sezary cells with positive clone | |
The staging of Sezary syndrome is based on the clinical stages:[5][6]
| clinical stages | |||||
|---|---|---|---|---|---|
| Stage | T | N | M | B | DDS |
| IA | 1 | 0 | 0 | 0/1 | 98 |
| IB | 2 | 0 | 0 | 0/1 | 89 |
| IIA | 1.2 | 1.2 | 0 | 0/1 | 89 |
| IIB | 3 | 0-2 | 0 | 0/1 | 56 |
| IIIA | 4 | 0-2 | 0 | 0 | 54 |
| IIIB | 4 | 0-2 | 0 | 1 | 48 |
| IVA1 | 1-4 | 0-2 | 0 | 2 | 41 |
| IVA2 | 1-4 | 3 | 0 | 0-2 | 23 |
| IVB | 1-4 | 0-3 | 1 | 0-2 | 18 |
- [5-year disease free survival (DSS)]
- Summary of taging for cutaneous T cell lymphoma is provided in the following table:[1][2][3][4]
| Stage | Clinical description | Tomur (T) | Node (N) | Metastasis (M) | Blood (B) |
|---|---|---|---|---|---|
| IA | Limited patch or plaque <10% | T1 | N0 | M0 | 0-1 |
| IB | Generalized patch or pluque>10% | T2 | N0 | M0 | 0-1 |
| IIB | Tumors +/- adenophaty | T3 | N0-N2 | M0 | 0-1 |
| IIA | Patch or plaque + adenopathy | T1-T2 | N1-N2 | M0 | 1-2 |
| III | Erithroderma +/- adenopathy | T4 | N0-N2 | M0 | 0-2 |
| IVA | Histologically + nodes (Sezary syndrome) | T1-T4 | N0-N3 | M0 | 0-2 |
| IVB | Visceral involvement | T1-T4 | N0-N2 | M1 | 0-2 |
References
- ↑ 1.0 1.1 1.2 Cutaneous T cell lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/cutaneous-t-cell-lymphoma/?region=on Accessed on January 19, 2016
- ↑ 2.0 2.1 Olsen, E.; Vonderheid, E.; Pimpinelli, N.; Willemze, R.; Kim, Y.; Knobler, R.; Zackheim, H.; Duvic, M.; Estrach, T.; Lamberg, S.; Wood, G.; Dummer, R.; Ranki, A.; Burg, G.; Heald, P.; Pittelkow, M.; Bernengo, M.-G.; Sterry, W.; Laroche, L.; Trautinger, F.; Whittaker, S. (2007). "Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)". Blood. 110 (6): 1713–1722. doi:10.1182/blood-2007-03-055749. ISSN 0006-4971.
- ↑ 3.0 3.1 Liner, Kendall; Brown, Celeste; McGirt, Laura (2018). "Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data". Drug Design, Development and Therapy. Volume 12: 241–254. doi:10.2147/DDDT.S137106. ISSN 1177-8881.
- ↑ 4.0 4.1 Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo MG, Sterry W, Laroche L, Trautinger F, Whittaker S (September 2007). "Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)". Blood. 110 (6): 1713–22. doi:10.1182/blood-2007-03-055749. PMID 17540844.
- ↑ Invalid
<ref>tag; no text was provided for refs namedTrautingerEder2017 - ↑ Jawed, Sarah I.; Myskowski, Patricia L.; Horwitz, Steven; Moskowitz, Alison; Querfeld, Christiane (2014). "Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)". Journal of the American Academy of Dermatology. 70 (2): 205.e1–205.e16. doi:10.1016/j.jaad.2013.07.049. ISSN 0190-9622.